We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Recursion (RXRX) is expected to provide updates on its oncology and rare disease clinical-stage pipeline in its first-quarter earnings release, given the absence of a marketed product.
Fusion (FUSN) is expected to provide updates regarding the developmental program of its lead candidate, FPI-2265, for prostate cancer in the first-quarter earnings release.
ALX Oncology (ALXO) announces positive results from an early to mid-stage study of an investigational combination regimen to treat indolent and aggressive R/R B-NHL.
Nurix (NRIX) rises on initial findings of clinical responses in the brain for its investigational targeted protein degrader, NX-5948, which is currently under development to treat B cell malignancies.
Cardiff (CRDF) surges 194% in the past month, driven by investors' optimism regarding the potential of its investigational candidate, onvansertib, to treat first-line patients with RAS-mutated mCRC.
oncology-screening: Archive
Guardant (GH) Gears Up for Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Investors' focus will likely be on revenues generated by Guardant Health (GH) from its precision oncology testing business.
ANIPNegative Net Change ANABPositive Net Change ARGXNegative Net Change GHNegative Net Change
biotechs medical oncology-screening
Recursion (RXRX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Recursion (RXRX) is expected to provide updates on its oncology and rare disease clinical-stage pipeline in its first-quarter earnings release, given the absence of a marketed product.
CPRXNegative Net Change ADVMNegative Net Change ARGXNegative Net Change RXRXNegative Net Change
biotechnology biotechs earnings medical oncology-screening pharmaceuticals
GE Healthcare's (GEHC) Revolution RT to Aid Cancer Treatment
by Zacks Equity Research
GE Healthcare (GEHC) unveils Revolution RT, along with other upgrades, from its portfolio during the ESTRO 2024 Congress.
BSXNegative Net Change ECLPositive Net Change ALGNNegative Net Change GEHCNegative Net Change
artificial-intelligence medical-devices messenger-rna oncology-screening
Veru Inc. (VERU) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
VERUNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Fusion (FUSN) to Report Q1 Earnings: Here's What to Expect
by Zacks Equity Research
Fusion (FUSN) is expected to provide updates regarding the developmental program of its lead candidate, FPI-2265, for prostate cancer in the first-quarter earnings release.
AZNPositive Net Change MRKNegative Net Change SRPTNegative Net Change FUSNNo Net Change
biotechnology biotechs earnings medical oncology-screening pharmaceuticals
Royal Gold (RGLD)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
RGLDNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
After Golden Cross, CuriosityStream Inc. (CURI)'s Technical Outlook is Bright
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
CURINegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
SNDL Inc. (SNDL) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
SNDLNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Precision BioSciences (DTIL) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
DTILPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
ALX Oncology (ALXO) Posts Upbeat Results From Lymphoma Study
by Zacks Equity Research
ALX Oncology (ALXO) announces positive results from an early to mid-stage study of an investigational combination regimen to treat indolent and aggressive R/R B-NHL.
RHHBYNegative Net Change BMYNegative Net Change ALXONegative Net Change NRIXNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Nurix (NRIX) Up on Upbeat Initial Data From Phase I Cancer Study
by Zacks Equity Research
Nurix (NRIX) rises on initial findings of clinical responses in the brain for its investigational targeted protein degrader, NX-5948, which is currently under development to treat B cell malignancies.
SNYPositive Net Change AZNPositive Net Change RHHBYNegative Net Change NRIXNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
Agilent (A) is Set for Analytica 2024 With Advanced Products
by Zacks Equity Research
Agilent (A) plans to showcase its new products for analytical laboratories at Analytica 2024, boosting its overall product portfolio.
APositive Net Change INCYNegative Net Change AMENegative Net Change AMATPositive Net Change
gene-therapy genomics oncology-screening tech-stocks
Intellicheck Mobilisa, Inc. (IDN) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
IDNPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Agilent (A) to Bolster DCG Segment With Upcoming Solutions
by Zacks Equity Research
Agilent (A) plans to introduce new solutions for cancer research and diagnosis, boosting its DCG segment.
APositive Net Change AMENegative Net Change AMATPositive Net Change BLNegative Net Change
genomics medical oncology-screening tech-stocks
International Consolidated Airlines Group SA (ICAGY)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
ICAGYPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Fuel Tech, Inc. (FTEK)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
FTEKPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
After Golden Cross, J.Jill (JILL)'s Technical Outlook is Bright
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
JILLNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
McEwen (MUX) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
MUXPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Aligos Therapeutics, Inc. (ALGS) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
ALGSNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
After Golden Cross, Shell (SHEL)'s Technical Outlook is Bright
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
SHELNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
OPENLANE (KAR) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
KARNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Kaiser Aluminum (KALU)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
KALUNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Cipher Mining Inc. (CIFR) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
CIFRNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Repsol SA (REPYY) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
REPYYPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Cardiff (CRDF) Stock Rallies 194% in a Month: Here's Why
by Zacks Equity Research
Cardiff (CRDF) surges 194% in the past month, driven by investors' optimism regarding the potential of its investigational candidate, onvansertib, to treat first-line patients with RAS-mutated mCRC.
PFEPositive Net Change ADMANegative Net Change FGENNegative Net Change CRDFNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals